NASD · Healthcare · Biotechnology · USA
Axsome Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Axsome Therapeutics is a biopharmaceutical company developing medicines for central nervous system conditions. The company markets three FDA-approved products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for acute migraine treatment. It also maintains a pipeline of investigational candidates, including AXS-05 for Alzheimer's disease agitation and smoking cessation, and solriamfetol for various neurological and psychiatric disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Axsome Therapeutics Inc stock.
Overvalued: intrinsic value $65.57 per share, market price $155.81, margin of safety -137.6% (as of 2026-10-19).
A 4.2x revenue multiple, discounted for its losses, values the shares at $65.57; the price of $155.81 is 138% above that value.
17 more funds hold it; the full list is part of the paid plan.
64 more in this industry show a wider margin of safety.
AXSM is overvalued (as of the 2026-10-19 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $65.57; the price of $155.81 is 138% above that value.
$65.57 per share (as of the 2026-10-19 close), against a market price of $155.81. That is a margin of safety of -137.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.